Summary

Eligibility
for people ages 40 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Mehrdad Arjomandi (ucsf)
Headshot of Mehrdad Arjomandi
Mehrdad Arjomandi

Description

Summary

This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.

Official Title

Occult Cardiovascular Disease With Chronic Exposure to Secondhand Tobacco Smoke

Details

Keywords

Cardiovascular Diseases, Hypertension, Second Hand Tobacco Smoke, Losartan, Antihypertensive Agents, Angiotensin II, Angiotensin Receptor Antagonists

Eligibility

Location

  • San Francisco Veterans' Affairs Medical Center accepting new patients
    San Francisco California 94121 United States

Lead Scientist at University of California Health

  • Mehrdad Arjomandi (ucsf)
    Dr. Arjomandi grew up in Ahvaz, a small city in Southwestern Iran, and moved to the United States in 1986 in the aftermath of Iranian revolution (1979), Iraq's invasion of Iran (1980-88), and his family displacement inside Iran (1980-83).

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
Links
University of California, San Francisco (UCSF) website for Arjomandi Lab
ID
NCT04715568
Phase
Phase 4 research study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated